Implementation and Outcomes of COVID-19 Vaccinations at a Child and Adolescent Psychiatric Hospital

Increasing coronavirus disease 2019 (COVID-19) vaccination rates has been identified by the US Centers of Disease Control and Prevention as critical to ending the COVID-19 pandemic.(1) On May 10, 2021, the Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Pfizer, Inc, New York, New York, and BioNTech SE,...

Descripción completa

Detalles Bibliográficos
Autores principales: Moeller, Karen E., Meeks, Matie, Reynoldson, Jill, Douglass, Michell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Child and Adolescent Psychiatry 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410143/
https://www.ncbi.nlm.nih.gov/pubmed/34481918
http://dx.doi.org/10.1016/j.jaac.2021.08.018
Descripción
Sumario:Increasing coronavirus disease 2019 (COVID-19) vaccination rates has been identified by the US Centers of Disease Control and Prevention as critical to ending the COVID-19 pandemic.(1) On May 10, 2021, the Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Pfizer, Inc, New York, New York, and BioNTech SE, Mainz, Germany) was approved for emergency use authorization by the US Food and Drug Administration for patients 12 years of age or older. Here we report a retrospective study describing the implementation of a COVID-19 vaccination program at our child and adolescent psychiatric hospital. To our knowledge, this is the first report detailing the administration of the COVID-19 vaccination in this setting.

Ejemplares similares